259 related articles for article (PubMed ID: 23595562)
1. An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®.
Kaufman JM; Palacios S; Silverman S; Sutradhar S; Chines A
Osteoporos Int; 2013 Oct; 24(10):2561-9. PubMed ID: 23595562
[TBL] [Abstract][Full Text] [Related]
2. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
Kanis JA; Johansson H; Oden A; McCloskey EV
Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
[TBL] [Abstract][Full Text] [Related]
3. FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.
Harvey NC; Kanis JA; Odén A; Burge RT; Mitlak BH; Johansson H; McCloskey EV
Osteoporos Int; 2015 Nov; 26(11):2677-84. PubMed ID: 26092063
[TBL] [Abstract][Full Text] [Related]
4. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA
Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589
[TBL] [Abstract][Full Text] [Related]
5. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.
Silverman SL; Chines AA; Kendler DL; Kung AW; Teglbjærg CS; Felsenberg D; Mairon N; Constantine GD; Adachi JD;
Osteoporos Int; 2012 Jan; 23(1):351-63. PubMed ID: 21779819
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX.
Harvey NC; Kanis JA; Odén A; Nakamura T; Shiraki M; Sugimoto T; Kuroda T; Johansson H; McCloskey EV
Osteoporos Int; 2015 Sep; 26(9):2347-53. PubMed ID: 26092062
[TBL] [Abstract][Full Text] [Related]
7. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.
Reginster JY; Kaufman JM; Goemaere S; Devogelaer JP; Benhamou CL; Felsenberg D; Diaz-Curiel M; Brandi ML; Badurski J; Wark J; Balogh A; Bruyère O; Roux C
Osteoporos Int; 2012 Mar; 23(3):1115-22. PubMed ID: 22124575
[TBL] [Abstract][Full Text] [Related]
8. Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm.
Kim K; Svedbom A; Luo X; Sutradhar S; Kanis JA
Osteoporos Int; 2014 Jan; 25(1):325-37. PubMed ID: 24114398
[TBL] [Abstract][Full Text] [Related]
9. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).
Kanis JA; Johansson H; Oden A; McCloskey EV
Osteoporos Int; 2011 Aug; 22(8):2347-55. PubMed ID: 21287148
[TBL] [Abstract][Full Text] [Related]
10. Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study.
McCloskey EV; Johansson H; Harvey NC; Lorentzon M; Shi Y; Kanis JA
Osteoporos Int; 2021 Aug; 32(8):1601-1608. PubMed ID: 33537844
[TBL] [Abstract][Full Text] [Related]
11. Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial.
Donaldson MG; Palermo L; Ensrud KE; Hochberg MC; Schousboe JT; Cummings SR
J Bone Miner Res; 2012 Aug; 27(8):1804-10. PubMed ID: 22492479
[TBL] [Abstract][Full Text] [Related]
12. Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women.
Ellis AG; Reginster JY; Luo X; Bushmakin AG; Williams R; Sutradhar S; Mirkin S; Jansen JP
Curr Med Res Opin; 2014 Aug; 30(8):1617-26. PubMed ID: 24773456
[TBL] [Abstract][Full Text] [Related]
13. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
[TBL] [Abstract][Full Text] [Related]
14. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial.
Delmas PD; Genant HK; Crans GG; Stock JL; Wong M; Siris E; Adachi JD
Bone; 2003 Oct; 33(4):522-32. PubMed ID: 14555255
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.
Silverman SL; Christiansen C; Genant HK; Vukicevic S; Zanchetta JR; de Villiers TJ; Constantine GD; Chines AA
J Bone Miner Res; 2008 Dec; 23(12):1923-34. PubMed ID: 18665787
[TBL] [Abstract][Full Text] [Related]
16. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective.
Borgström F; Ström O; Kleman M; McCloskey E; Johansson H; Odén A; Kanis JA
Osteoporos Int; 2011 Mar; 22(3):955-65. PubMed ID: 20532482
[TBL] [Abstract][Full Text] [Related]
18. Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
Leder BZ; Mitlak B; Hu MY; Hattersley G; Bockman RS
J Clin Endocrinol Metab; 2020 Mar; 105(3):938-43. PubMed ID: 31674644
[TBL] [Abstract][Full Text] [Related]
19. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
Meunier PJ; Roux C; Ortolani S; Diaz-Curiel M; Compston J; Marquis P; Cormier C; Isaia G; Badurski J; Wark JD; Collette J; Reginster JY
Osteoporos Int; 2009 Oct; 20(10):1663-73. PubMed ID: 19153678
[TBL] [Abstract][Full Text] [Related]
20. Current challenges in the treatment of osteoporosis: an opportunity for bazedoxifene.
Reginster JY; Ferrari S; Hadji P
Curr Med Res Opin; 2014 Jun; 30(6):1165-76. PubMed ID: 24495098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
